PHARMACODYNAMIC ACTION OF VIRECHANA KARMA IN MADHUMEHA (TYPE 2 DIABETES MELLITUS

Abstract

Background: Madhumeha, described under the spectrum of Prameha in classical Ayurvedic literature, closely resembles Type 2 Diabetes Mellitus (T2DM), a chronic metabolic disorder characterized by insulin resistance, β-cell dysfunction, chronic low-grade inflammation, oxidative stress, and metabolic endotoxemia.[1,3] Ayurveda attributes its pathogenesis to Kapha-Pitta aggravation, Medo-dhatu vriddhi, Agnimandya, and Srotorodha.[4,7] Objective: To explore the pharmacodynamic basis of Virechana Karma in Madhumeha through classical Ayurvedic principles and contemporary molecular mechanisms. Materials and Methods: Classical Ayurvedic texts including Charaka Samhita, Sushruta Samhita, and Ashtanga Hridaya were critically reviewed. Contemporary biomedical literature addressing insulin resistance, inflammatory signaling, oxidative stress, gut microbiota, bile acid signaling, hepatometabolic regulation, and neuroendocrine stress pathways was analyzed. Conceptual correlations were constructed using a systems biology framework. Results: Virechana Karma, the principal Pittahara Shodhana therapy, may modulate inflammatory cytokines (TNF-α, IL-6, IL-1β), improve insulin signaling (IRS-1/PI3K/Akt pathway), reduce oxidative stress, alter gut microbial composition, enhance bile acid receptor activation (FXR/TGR5), and recalibrate neuroendocrine stress responses. These interconnected mechanisms correspond to classical concepts of Agni Deepana, Ama Pachana, Srotoshodhana, and Dosha Shamana. Conclusion: Virechana may exert multi-system pharmacodynamic effects relevant to Madhumeha. Rigorous translational research integrating molecular biomarkers and randomized clinical trials is essential for scientific validation and global integration.